10-K: Sotera Health Sees Revenue Growth Amidst Legal Challenges

Sotera Health Company reported a 5.7% increase in net revenues to $1,163.6 million for 2025, alongside significant legal settlements and ongoing environmental litigation.

Summary

• Net revenues increased by 5.7% to $1,163.6 million in 2025, up from $1,100.4 million in 2024.
• Net income rose by 75.6% to $77.9 million in 2025, compared to $44.4 million in 2024.
• Adjusted Net Income increased by 23.6% to $245.4 million in 2025, from $198.5 million in 2024.
• Adjusted EBITDA grew by 8.2% to $593.8 million in 2025, up from $548.6 million in 2024.
• Service revenues increased by $53.9 million (5.7%) to $995.8 million, driven by favorable pricing and volume/mix in the Sterigenics and Nelson Labs segments.
• Product revenues increased by $9.2 million (5.8%) to $167.9 million, primarily due to volume/mix growth and favorable pricing.
• SG&A expenses increased by $10.1 million (4.2%) to $252.8 million, mainly due to a $13.5 million increase in litigation and other professional services expense associated with EO sterilization facilities.
• Amortization of intangible assets decreased by $31.3 million (50.5%) to $30.7 million, primarily due to certain intangible assets being fully amortized.
• Interest expense, net, decreased by $9.0 million (5.4%) to $155.7 million, attributed to a lower weighted average interest rate on outstanding borrowings (7.29% in 2025 vs. 8.16% in 2024).
• Settled Illinois EO claims for $30.9 million in April 2025 and an additional $34.0 million in July 2025.
• Cash and cash equivalents increased by $67.6 million to $346.5 million as of December 31, 2025.
• Total indebtedness was approximately $2,169.5 million as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting solid revenue and earnings growth, successful debt refinancing, and progress in addressing some legal challenges, despite ongoing litigation risks and a decline in one segment's revenue.

Positives

• Net revenues increased by 5.7% to $1,163.6 million in 2025, demonstrating solid top-line growth.
• Net income surged by 75.6% to $77.9 million, indicating improved profitability.
• Adjusted EBITDA grew by 8.2% to $593.8 million, reflecting strong operational performance.
• Sterigenics and Nordion segments showed robust revenue growth of 8.3% and 8.2% respectively.
• Successful debt refinancing led to a lower weighted average interest rate of 7.29% in 2025, down from 8.16% in 2024, reducing interest expense by $9.0 million.
• Nordion's Class 1B nuclear license was renewed for a 25-year term in September 2025, ensuring long-term operational stability for a critical business segment.
• The company is actively investing in new sterilization modalities (X-ray, NO2-based) and expanding Co-60 supply through partnerships and projects like Darlington reactors, enhancing future capacity and diversification.
• The Sixth Circuit Court of Appeals affirmed the dismissal of the Michigan Funds Litigation, resolving a significant securities class action lawsuit.
• A $16.6 million tax benefit was recognized due to the reduction of a valuation allowance related to the One Big Beautiful Bill Act (OBBBA).

Negatives

• Nelson Labs segment experienced a 3.9% decrease in net revenues, primarily due to a 10.2% decline in expert advisory services and consulting revenue.
• Incurred significant litigation and other professional fees of $46.2 million in 2025 related to EO sterilization facilities.
• Paid $64.9 million in 2025 for settlements of Illinois EO litigation claims.
• Future environmental liability insurance policies exclude coverage for EO claims, increasing financial exposure to ongoing and potential new litigation.
• The proportion of Co-60 supply from Russian reactors could increase to as much as 50% in a given year, introducing heightened geopolitical and sanctions risks to a critical input.
• Experienced supply chain disruptions in 2025 due to a prolonged U.S. federal government shutdown, which could recur.
• Faces risks of increased input costs (labor, raw materials, energy) due to inflation and market conditions, with potential difficulty in fully passing these costs to customers.
• Maintains a significant degree of leverage with total indebtedness of approximately $2,169.5 million as of December 31, 2025.
• The company has a history of net losses and cannot assure sustained profitability in future periods.

Risks

• Disruption in the availability or supply of, or increases in the price of, ethylene oxide (EO), Cobalt-60 (Co-60), or other direct materials, services, and supplies, including as a result of geopolitical instability and/or sanctions against Russia.
• Fluctuations in foreign currency exchange rates impacting financial results.
• Evolving changes in environmental, health, and safety regulations, potentially increasing costs or altering customer preferences and demand for services.
• Health and safety risks associated with the use, storage, transportation, and disposal of potentially hazardous materials such as EO and Co-60, which may result in accidents or liabilities.
• The impact and outcome of current and future legal proceedings and liability claims, including extensive litigation related to the use, emissions, and releases of EO from current and former sterilization facilities, and the possibility of additional claims.
• Allegations of failure to properly perform services and potential product liability claims, recalls, penalties, and reputational harm.
• Compliance with extensive regulatory requirements, associated costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals.
• Adverse changes in industry trends, including shifts in preferred sterilization modalities (e.g., X-ray technology) or reduced demand for medical devices.
• Competition from other outsourced sterilization and lab services providers, in-house capabilities, and alternative technologies.
• Market conditions and changes, including inflationary trends and the impact of tariffs, affecting long-term supply contracts and increasing cost of revenues.
• Business continuity hazards, including supply chain disruptions (e.g., federal government shutdowns), natural disasters, and reliance on single locations.
• Risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable and potentially inconsistent laws and regulations.
• Inability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner, and renew leases for leased facilities.
• Inability to attract and retain qualified employees.
• Severe health events or environmental events, including impacts from climate change, and natural disasters.
• Cybersecurity incidents, unauthorized data disclosures, and dependence on information technology (IT) systems, including risks associated with the introduction of artificial intelligence (AI) technology.
• Inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into the business successfully.
• Inability to maintain effective internal control over financial reporting.
• Reliance on intellectual property rights to maintain competitive position and the risk of claims from third parties regarding infringement or misappropriation.
• Inability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions.
• Inability to maintain profitability in future periods.
• Impairment charges on goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives.
• The effects of unionization efforts and labor regulations in countries of operation.
• Adverse changes to tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in taxation.
• Significant degree of leverage adversely affecting ability to raise additional capital, react to challenges, limit flexibility through debt agreements, or prevent meeting obligations.
• Control by certain investment funds and entities affiliated with Warburg Pincus and GTCR (Sponsors) over the company.
• Volatility in the market and trading volume of common stock, potentially leading to loss of investment.
• Future issuance of additional common stock in connection with incentive plans, acquisitions, or otherwise, diluting other stockholdings.
• Future offerings of debt or equity securities adversely affecting the market price of common stock.
• A sale of a substantial number of shares of common stock, or the perception of such sales, causing the price of common stock to decline.
• The interests of the Sponsors potentially differing from the interests of other stockholders.
• Certain stockholders having the right to engage or invest in the same or similar businesses as the company.
• Anti-takeover provisions in the Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws, and Stockholders Agreement, as well as Delaware law, discouraging a change in control or management.
• Designation of specific courts as the exclusive forum for certain litigation initiated by stockholders, potentially limiting stockholders' abilities to obtain a favorable judicial forum.
• No anticipated payment of dividends on common stock in the foreseeable future, making stock price appreciation the sole source of potential gain.

Future Outlook

The company expects to continue investing in facility expansions, ongoing routine maintenance, and the acquisition of Co-60 for its Sterigenics segment in 2026. Special projects related to the development of new Co-60 supply sources and facility enhancements at EO sterilization facilities are also anticipated. Approximately $51 million in capital expenditures is projected for environmental facility enhancements in 2026. Management believes its investments in emission control and employee protection at EO facilities will enable compliance with updated NESHAP and FIFRA ID requirements. The proportion of Co-60 supply from Russian reactors is expected to increase to as much as 50% in a given year over the next few years, and litigation costs are expected to continue for the foreseeable future.

Management Comments

• "We continue to advance our growth-related investments, including our two active capacity expansion projects within the Sterigenics segment, Co-60 development projects in the Nordion segment and lab expansion efforts to support pharma testing services in the Nelson Labs segment."
• "We remain committed to our highly disciplined acquisition strategy and continue to seek suitable acquisition targets."
• "We believe that our investments in emission control enhancements and employee protection at our EO facilities have positioned us to be able to comply with the updated NESHAP and FIFRA ID requirements within the timeframes specified by the final rules or regulatory exemptions received."
• "We consistently meet or exceed regulatory emissions control requirements, although we have periodically experienced isolated instances of emissions exceeding applicable standards or other non-compliance, none of which we believe were material."
• "We continue to believe that the EO-related claims are without merit and intend to vigorously defend the remaining EO cases and any future EO cases."

Industry Context

StockSavvy.ai notes that the healthcare industry's reliance on mission-critical sterilization and lab testing services continues to drive demand, with regulatory requirements playing a significant role. The company's strategic investments in alternative sterilization modalities like X-ray and NO2-based sterilization align with broader industry trends seeking to diversify beyond traditional methods such as EO and gamma irradiation, especially in light of increasing regulatory scrutiny and supply chain vulnerabilities associated with Co-60. Nordion's partnerships for domestic Co-60 production (e.g., with Westinghouse and PSEG in the U.S.) and capacity expansion (Darlington reactors) are crucial steps to mitigate geopolitical risks and enhance supply chain robustness, reflecting a proactive approach to industry challenges.

Comparison to Industry Standards

• Sterigenics competes globally with Applied Sterilization Technologies (a segment of STERIS plc) and other smaller or regional outsourced sterilization companies, as well as in-house sterilization capabilities of manufacturers.
• Nordion's competitors in the Co-60 market, primarily in Argentina, India, and Russia, operate mainly in domestic markets with smaller export portions, suggesting Nordion maintains a strong global presence.
• Nordion also faces indirect competition from developing sterilization modalities like X-ray technology, which does not require Co-60 sources.
• Nelson Labs competes with a diverse range of providers, from small, specialized niche laboratories to large, broad multinational corporations and internal laboratories.
• Sterigenics' high historical customer retention rates (100% renewal for its top ten customers for over five consecutive years, and an average tenure of over a decade with its top 25 customers) indicate strong customer loyalty and competitive advantage within its market, likely exceeding typical industry averages for contract service providers.

Management Changes

Corporate Governance

Legal Proceedings

• **Ethylene Oxide Tort Litigation California (Vernon Cases)**: Approximately 120 claims for personal injury or wrongful death pending in Los Angeles County Superior Court as of February 20, 2026, with initial trials scheduled for January and April 2027. Eight individual claims are prioritized for discovery.
• **Ethylene Oxide Tort Litigation Georgia (Atlanta facility)**: Approximately 450 personal injury and wrongful death claims pending in the State Court of Cobb County as of February 20, 2026. The Georgia Trial Court granted Sterigenics' motions for summary judgment on specific causation in three Phase 2 Cases on October 17, 2025. The Court of Appeals of Georgia vacated the Phase 1 General Causation Ruling on October 31, 2025, remanding cases for proper standard application.
• **Ethylene Oxide Tort Litigation Georgia (Customer distribution facility)**: A lawsuit filed in May 2020 by employees of a sterilization customer alleging injury from residual EO from Sterigenics-sterilized products. The customer is contractually indemnifying Sterigenics against this lawsuit.
• **Ethylene Oxide Tort Litigation Georgia (Property devaluation)**: Approximately 305 lawsuits pending in the Georgia Trial Court against the company and other parties, alleging property devaluation from EO emissions. These cases are consolidated for pretrial purposes.
• **Ethylene Oxide Tort Litigation Illinois (Willowbrook Cases)**: One Willowbrook Case with two plaintiffs asserting personal injury claims is pending in the Circuit Court of Cook County, Illinois, as of February 20, 2026.
• **Ethylene Oxide Tort Litigation Illinois Settlements**: The company entered into binding term sheets to settle 97 pending and threatened EO claims for $30.9 million (finalized September 2025) and an additional 129 claims for $34.0 million (finalized February 2026). The company also settled with the remaining plaintiff who opted out of the January 2023 settlement in December 2025.
• **Ethylene Oxide Tort Litigation New Mexico (Santa Teresa facility)**: A lawsuit by the New Mexico Attorney General alleges air quality deterioration and increased health risks from EO emissions. The case is set for trial in July 2026. The Trial Court denied the NMAG's May 2025 motion to reinstate healthcare cost damages claim in January 2026.
• **Insurance Coverage for Environmental Liabilities**: The company's environmental liability insurance policy limits for EO tort lawsuits were fully utilized. Future alleged environmental liabilities exclude coverage for EO claims. Ongoing insurance coverage lawsuits are pending in the U.S. District Court for the Northern District of Illinois, Delaware Superior Court, and Los Angeles County Superior Court. The Illinois Supreme Court issued an opinion on pollution exclusion in January 2026.
• **Sotera Health Company Securities Litigation and Related Matters (Michigan Funds Litigation)**: A stockholder class action filed in January 2023, alleging securities law violations related to EO safety disclosures. The Ohio District Court granted the company's motion to dismiss on March 19, 2025, and the Sixth Circuit Court of Appeals affirmed this dismissal on February 24, 2026.
• **Sotera Health Company Securities Litigation and Related Matters (May 2024 Derivative Litigation)**: A stockholder derivative lawsuit filed in May 2024 in the Delaware Chancery Court, alleging breaches of fiduciary duties and other violations. This litigation is stayed pending the resolution of the Michigan Funds Appeal.
• **Sotera Health Company Securities Litigation and Related Matters (220 Demands)**: The company has received demands for inspection of its books and records from shareholders investigating potential wrongdoing.

Stakeholder Impact

• **Shareholders**: Experienced positive financial performance with increased net income and Adjusted EBITDA, but face ongoing uncertainty and potential financial impact from extensive EO tort litigation. The affirmation of the dismissal of the securities litigation is a positive development. Future equity offerings could lead to dilution.
• **Employees**: Subject to health and safety risks associated with handling hazardous materials like EO and Co-60. Unionization efforts and labor regulations could impact employment terms and costs. Share-based compensation plans are part of the compensation strategy.
• **Customers**: Benefit from high customer retention rates in Sterigenics and ongoing investments in new sterilization technologies. Supply chain disruptions and regulatory changes could affect service delivery and product safety compliance.
• **Suppliers**: The company's dependence on a limited number of suppliers for critical materials like EO and Co-60, particularly from Russia, exposes them to geopolitical and supply chain risks.
• **Creditors**: The company's significant leverage is a concern, but successful debt refinancing at a lower interest rate is favorable. Debt covenants impose restrictions on the company's operations.
• **Communities**: Ongoing EO tort litigation and community concerns regarding emissions from facilities highlight potential negative impacts on public health and property values in surrounding areas.

Next Steps

• Continue progressing certain changes to facilities to comply with the final NESHAP EO sterilizer regulation.
• Invest approximately $51 million in capital expenditures related to environmental facility enhancements in 2026.
• Continue to invest in facility expansions, ongoing routine maintenance for existing facilities, and acquisition of Co-60 for the Sterigenics segment.
• Invest in special projects related to the development of new Co-60 supply sources and facility enhancements at EO sterilization facilities.
• The Georgia Trial Court will conduct further Phase 1 proceedings in the five remanded pool cases.
• The New Mexico Attorney General case is set for trial in July 2026.
• Initial trials for the Vernon Cases in California are scheduled for January and April 2027.
• Licenses for Co-60 import from Russia and targets from North America to Russia require renewal in 2026 and 2027.
• Canadian CNSC licenses for Co-59 targets import/export expire in 2028.
• The Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders will be filed within 120 days after December 31, 2025.

Key Dates

Recommendation

Sotera Health demonstrates strong operational performance with revenue and EBITDA growth, and has successfully refinanced debt at a lower interest rate. The affirmation of the dismissal of the securities litigation is a positive. However, the company faces substantial and unpredictable risks from ongoing Ethylene Oxide (EO) tort litigation, which has already resulted in significant settlements and could lead to further material liabilities not covered by current insurance. The dependence on a limited Co-60 supply, particularly from Russia, introduces geopolitical risk. These factors create a balanced risk-reward profile, suggesting a "hold" recommendation until there is greater clarity on the ultimate financial impact of the litigation and supply chain stability.

Keywords

Sterilization, Ethylene Oxide, Cobalt-60, Gamma Irradiation, E-beam, X-ray, Lab Testing, Medical Devices, Pharmaceuticals, Food Safety, Nelson Labs, Sterigenics, Nordion, SEC Filing, 10-K, Financial Results, Litigation, Risk Management, Supply Chain, Regulatory Compliance, Healthcare Industry, Environmental Health and Safety, Corporate Governance, Debt Refinancing, Share-based Compensation